PENNSYLVANIA: Indegene is buying BioPharm Communications, a specialised marketing agency serving 17 of the world’s top 25 biopharma firms. The acquisition, announced on 1 October, will bolt adtech capabilities onto the Indian company’s commercialisation portfolio and cement its position in data-driven omnichannel marketing for global pharma.
BioPharm, based in New Hope, Pennsylvania, is part of Omnicom Health Group. It brings 20 years of expertise in omnichannel strategy, media planning and execution, and precision marketing powered by analytics and automation. The deal is being done through ILSL Inc., a subsidiary of Indegene Ltd.
The timing is strategic. Pharma companies are scrambling to transform their marketing as physicians favour limited engagement and regulatory complexities mount. Traditional healthcare agencies are struggling to keep pace. Meanwhile, companies are juggling mature product portfolios whilst ramping up capabilities for new launches—all whilst trying to boost productivity.
“BioPharm has built an impressive growth flywheel, with advanced tech capabilities, deep therapeutic expertise, and long-standing client relationships,” said Indegene chairman and chief executive Manish Gupta. “This acquisition reinforces our position as the preferred tech-native commercialisation partner for the life sciences industry.”
BioPharm president Steve Carickhoff said Indegene was a natural home given its innovation-first, employee-centric culture backed by strong technology platforms and a global delivery model. “Their life sciences-contextualised approach to AI will open up new possibilities. Together, we will push the boundaries of AI-powered pharma marketing worldwide—delivering more personalised, measurable, and patient-focused outcomes.”
BioPharm operates a proprietary network of more than 3 million healthcare decision-makers, which it uses for precision targeting and addressable media campaigns. Combined with Indegene’s data assets, the acquisition should drive higher media returns on investment and enable more effective automated operations.
Indegene, listed on the BSE and NSE, describes itself as the tech-native life sciences specialist that orchestrates the path from commercialisation strategy through execution. It works with the world’s top 20 biopharma companies across clinical, medical and commercial functions. Founded 25 years ago, the company is headquartered in Bengaluru.
Seyfarth Shaw represented Indegene in the transaction.





